Practical Considerations for the Management of Cancer-Associated Venous Thromboembolism: A Guide for the General Oncology Practitioner.

Amye M Harrigan, Josée Rioux, Sudeep Shivakumar

Open access · goldAbstract readReview

In one paragraph

Review in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.4field-weighted citation impact, top 37% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

Intracerebral hemorrhage risk in glioma patients taking direct oral anticoagulants as compared with low molecular weight heparin.Neuro-oncology advances
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Amye M HarriganDepartment of Medicine, Division of Hematology, Dalhousie University, Nova Scotia Health, Halifax, NS B3H 2Y9, Canada.ORCID 0000-0002-2742-2305

Josée RiouxDepartment of Pharmacy, Nova Scotia Health, Victoria General Site, Halifax, NS B3H 2Y9, Canada.

Sudeep ShivakumarDepartment of Medicine, Division of Hematology, Dalhousie University, Nova Scotia Health, Halifax, NS B3H 2Y9, Canada.

Dalhousie University · CANova Scotia Health Authority · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer-associated venous thromboembolism is a devastating complication of cancer and is associated with significant morbidity and mortality. The cornerstone of cancer-associated venous thromboembolism treatment is anticoagulation, and in recent years, there have been notable randomized clinical trials that have revealed insights into the efficacy and safety of direct oral anticoagulants and low-molecular-weight heparin in the treatment of cancer-associated thrombosis. Deciding on the ideal anticoagulation treatment plan for a patient with a cancer-associated thrombosis is a complex task that requires an understanding of clinical trial data, society guidelines, and, most importantly, consideration of many cancer-related, treatment-related, and patient-related factors. This article summarizes important factors to consider when deciding on anticoagulation therapy for a patient with cancer-associated thrombosis.

Indexed as

NeoplasmsThrombosisVenous ThromboembolismAnticoagulantsHeparin, Low-Molecular-WeightHumansAnticoagulantsHeparin, Low-Molecular-Weightcancer-associated venous thromboembolismdirect oral anticoagulantlow-molecular-weight heparin

Identifiers

PMID36135074

DOI10.3390/curroncol29090505

PMCPMC9497708

OpenAlexW4296109071

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.